What top creators are saying about InMune Bio Inc.(INMB)

Mentioned as a negative comparison, cited as an example of a 'failed biotech story' similar to the speaker's thesis on ATYR.

Mentioned as a 'decent short' idea.

Mentioned as a past, highly successful short position for the speaker. It was his single biggest winner, contributing 43% to his portfolio's performance. The commentary is historical.

Mentioned as the speaker's biggest past profit, which came from a successful short position. No current forward-looking analysis was provided.

Mentioned as the speaker's biggest winning trade in the portfolio, up 44%, reflecting a past successful bullish call.

The speaker's biggest short position, calling it a 'piece of junk' with a price target of '$0.50 at some point' due to flawed clinical trial design.

The speaker holds a clear bearish position, explicitly stating, 'No, I'm still short INMB.'

Speaker is short the stock, believing it is 'basically worthless' and plans to cover the short position if the stock drops to $1.

The speaker is actively short and believes the stock has '75% downside' with a price target of $0.50, claiming the company has nothing of value in its pipeline and will waste its cash.

The analyst is extremely bearish, stating the Phase 2 trial for its drug Xpro failed. The company's positive spin on a subgroup is called 'a joke' and 'face-saving'. The plan to seek a partner is interpreted as a euphemism for 'giving up on the drug'.

The speaker is extremely bearish and holds a short position, believing the stock will fall significantly after its Phase 2 trial failed to meet its primary cognitive endpoint. The company's focus on a positive subgroup analysis is viewed as a misleading tactic.

The company's drug trial for Alzheimer's disease failed its primary endpoint, with the placebo group performing better. The company is characterized as misleadingly spinning subgroup analysis, the drug has significant safety issues (80% injection site reactions), and its weak financial position ($19M cash vs $6M quarterly burn) is expected to cause the stock to trade below its cash value.

The company's recent registered direct offering at a massive discount ($6.30 vs $14 market price) is seen as a signal of desperation and management's belief that upcoming clinical data will be negative. This is viewed as a high-conviction short opportunity.

The speaker is actively short the stock and believes its Phase 2 Alzheimer's trial will fail due to a flawed drug mechanism, predicting the stock will drop 90% very soon.

The speaker is extremely bearish ahead of imminent clinical trial data for an Alzheimer's drug, stating 'I'm pretty sure it's gonna fail.' He believes a failure could send the stock to $0.50 or cause bankruptcy and suggests buying puts.